LIPOPROTEIN (A) AS AN INDEPENDENT RISK FACTOR FOR MYOCARDIAL-INFARCTION IN PATIENTS WITH COMMON HYPERCHOLESTEROLEMIA

被引:16
作者
WATTS, GF [1 ]
KEARNEY, EM [1 ]
TAUB, NA [1 ]
SLAVIN, BM [1 ]
机构
[1] ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND
关键词
D O I
10.1136/jcp.46.3.267
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To examine whether protein (a) (Lp(a)) increases the risk of myocardial infarction (MI) in patients with common hypercholesterolaemia. Methods: 15 middle aged men with common hypercholesterolaemia (mean serum low density lipoprotein (LDL) cholesterol 4.94 mmol/l, SD 1.0) and a history of MI were selected consecutively from referrals to a lipid clinic. A control group that had not sustained an MI and with similar age, sex, cigarette smoking and blood pressure characteristics was also selected from the same clinic. Serum cholesterol, triglyceride, LDL cholesterol, high density lipoprotein cholesterol, apolipoproteins AI and B and Lp(a) were measured in both groups. Lp(a) was assayed by immunoturbidity. Results: The serum concentration of Lp(a) was significantly higher in patients with MI (geometric mean 0.64 (95% confidence interval 0.36 to 1.14) v 0.30 (0.21 to 0.42) g/l, p = 0.02), but there were no significant differences in other variables. Stepwise logistic regression analysis showed that Lp(a) was the only significant predictor of MI (p < 0.02). The odds ratio of Mi (adjusted for age, smoking, blood pressure and apolipoprotein B) for an Lp(a) of >0.57 g/l was 16.5, 95% confidence interval 2.3 to 125.4 (p = 0.001). Conclusion: In middle aged men with common hypercholesterolaemia the serum concentration of Lp(a) is a powerful and independent risk factor for MI. Lp(a) should probably be routinely measured in all patients referred to a lipid clinic.
引用
收藏
页码:267 / 270
页数:4
相关论文
共 32 条
  • [11] LIPIDS AND THROMBOSIS
    GASSER, JA
    BETTERIDGE, DJ
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1990, 4 (04): : 923 - 938
  • [12] LIPOPROTEIN(A) MODULATION OF ENDOTHELIAL-CELL SURFACE FIBRINOLYSIS AND ITS POTENTIAL ROLE IN ATHEROSCLEROSIS
    HAJJAR, KA
    GAVISH, D
    BRESLOW, JL
    NACHMAN, RL
    [J]. NATURE, 1989, 339 (6222) : 303 - 305
  • [13] HYPERLIPIDEMIA IN CORONARY HEART-DISEASE .3. EVALUATION OF LIPOPROTEIN PHENOTYPES OF 156-GENETICALLY DEFINED SURVIVORS OF MYOCARDIAL-INFARCTION
    HAZZARD, WR
    GOLDSTEIN, JL
    SCHROTT, HG
    MOTULSKY, AG
    BIERMAN, EL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (07) : 1569 - 1577
  • [14] KNIGHT BL, 1991, ATHEROSCLEROSIS, V87, P277
  • [15] MACKNESS MI, 1992, COMMUNICATION LABORA, V2, P499
  • [16] LIPOPROTEIN(A) - STRUCTURE, PROPERTIES AND POSSIBLE INVOLVEMENT IN THROMBOGENESIS AND ATHEROGENESIS
    MBEWU, AD
    DURRINGTON, PN
    [J]. ATHEROSCLEROSIS, 1990, 85 (01) : 1 - 14
  • [17] CDNA SEQUENCE OF HUMAN APOLIPOPROTEIN(A) IS HOMOLOGOUS TO PLASMINOGEN
    MCLEAN, JW
    TOMLINSON, JE
    KUANG, WJ
    EATON, DL
    CHEN, EY
    FLESS, GM
    SCANU, AM
    LAWN, RM
    [J]. NATURE, 1987, 330 (6144) : 132 - 137
  • [18] A POTENTIAL BASIS FOR THE THROMBOTIC RISKS ASSOCIATED WITH LIPOPROTEIN(A)
    MILES, LA
    FLESS, GM
    LEVIN, EG
    SCANU, AM
    PLOW, EF
    [J]. NATURE, 1989, 339 (6222) : 301 - 303
  • [19] IMMUNOTURBIDIMETRIC ASSAYS FOR SERUM APOLIPOPROTEIN-A1 AND APOLIPOPROTEIN-B USING COBAS BIO CENTRIFUGAL ANALYZER
    MOUNT, JN
    KEARNEY, EM
    ROSSENEU, M
    SLAVIN, BM
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (04) : 471 - 474
  • [20] LIPOPROTEIN(A) IN SUBJECTS WITH FAMILIAL DEFECTIVE APOLIPOPROTEIN-B100
    PEROMBELON, YFN
    GALLAGHER, JJ
    MYANT, NB
    SOUTAR, AK
    KNIGHT, BL
    [J]. ATHEROSCLEROSIS, 1992, 92 (2-3) : 203 - 212